



Repositorio Institucional de la Universidad Autónoma de Madrid

<https://repositorio.uam.es>

Esta es la **versión de autor** del artículo publicado en:
This is an **author produced version** of a paper published in:

Organic Letters 20.11 (2018): 3179-3182

DOI: <http://doi.org/10.1021/acs.orglett.8b00936>

Copyright: © 2018 American Chemical Society

El acceso a la versión del editor puede requerir la suscripción del recurso
Access to the published version may require subscription

1 Cu^I-Catalyzed Asymmetric [3 + 2] Cycloaddition of Azomethine Ylides with Cyclobutenones


3 Javier Corpas,^{†,§} Alberto Ponce,^{†,§} Javier Adrio,^{*,†,‡,§} and Juan C. Carretero^{*,†,‡}

4 [†]Departamento de Química Orgánica, Facultad de Ciencias, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain

5 [‡]Institute for Advanced Research in Chemical Sciences (IAdChem), Universidad Autónoma de Madrid, 28049 Madrid, Spain

6 **S** Supporting Information

7 **ABSTRACT:** The catalytic asymmetric 1,3-dipolar cyclo-
8 addition of cyclobutenones with azomethine ylides provides
9 straightforward access to densely substituted 3-
10 azabicyclo[3.2.0]heptanes. In the presence of Cu^I/(R)-
11 Fesulphos as the catalytic system, high levels of diastereose-
12 lectivity and enantioselectivity were achieved (up to 98% enantiomeric excess (ee)).



13 **T**he availability of efficient procedures for the straightfor-
14 ward preparation of substituted pyrrolidines is an
15 important issue in synthetic and medicinal chemistry, since
16 this heterocyclic unit is a key component in numerous
17 biologically active compounds and catalysts.¹ In particular, 3-
18 azabicyclo[3.2.0]heptanes derivatives shown interesting bio-
19 logical properties are receiving growing interest in drug
20 discovery, because of their use as conformationally constrained
21 surrogates for the piperidine ring² (see Figure 1). However, the
22 lack of efficient synthetic procedures for the enantioselective
23 preparation of azabicycloheptanes has limited their applic-
24 ability.³





Figure 1. Biologically active 3-azabicyclo[3.2.0]-heptanes.

25 In the last two decades, the catalytic asymmetric 1,3-dipolar
26 cycloaddition of azomethine ylides with activated olefins has
27 become a privileged strategy within the synthetic chemists'
28 toolbox for the enantioselective synthesis of pyrrolidines.⁴ The
29 impressive effort devoted in this field to develop new catalytic
30 systems has greatly facilitated expansion of the structural scope
31 with regard to both reaction partners.⁵ In this context, α,β -
32 unsaturated enones have emerged as one of the most useful
33 dipolarophiles in this catalytic asymmetric transformation. Since
34 the first report by our research group in 2009,⁶ a wide range of
35 suitable enones has been studied.⁷ However, the use of β,β -
36 disubstituted enones, which would enable the preparation of
37 pyrrolidines with a quaternary stereocenter at the C₃ position,
38 remains particularly challenging, because of the high sensitivity


of the reaction to steric effects at the dipolarophile. Very
recently, Zhang and co-workers have described access to
enantioenriched pyrrolidines bearing a quaternary stereocenter
at C₃ by a copper(I)-catalyzed [3 + 2] cycloaddition of
azomethine ylides with β -CF₃- β,β -substituted enones (Scheme
1, eq 1).⁸ In contrast, to the best of our knowledge,

Scheme 1. β,β -Disubstituted Enones as Dipolarophiles in Enantioselective 1,3-Dipolar Cycloadditions of Azomethine Ylides

a) Previous work: β -CF₃- β,β -disubstituted enones




b) This work: arylcyclobutenones



tetrasubstituted or β,β -disubstituted enones lacking an
electron-withdrawing group in the beta position have not
been reported so far.

On the other hand, cyclobutenones have proven to be
excellent dipolarophiles in Diels–Alder reactions, because of
their ring strain, which makes the reaction much more favorable
than in the case of cyclopentenones or cyclohexenones.⁹ As far
as we are aware, the use of cyclobutenones as dipolarophiles in
enantioselective 1,3-dipolar cycloadditions of azomethine ylides
has not been previously reported. Taking advantage of the ring
strain of the cyclobutenone moiety, we envisaged that sterically

Table 1. Optimization of the Reaction Conditions



entry	[M]	solvent	base	ligand	yield ^d (%)	endo/exo ^b	ee ^c (%)
1	AgOAc	THF	Et ₃ N	(±)-binap (4)			
2	Cu(CH ₃ CN) ₄ PF ₆	THF	Et ₃ N	(±)-binap (4)			
3	AgOAc	THF	KHMDS	(±)-binap (4)	53	>98:2	
4	AgOAc	THF	KO ^t Bu	(±)-binap (4)	52	>98:2	
5	Cu(CH ₃ CN) ₄ PF ₆	THF	KHMDS	(±)-binap (4)	62	>98:2	
6	Cu(CH ₃ CN) ₄ PF ₆	THF	KO ^t Bu	(±)-binap (4)	64	>98:2	
7	Cu(CH ₃ CN) ₄ PF ₆	THF	KO ^t Bu	(R)-binap (4)	38	>98:2	36
8	Cu(CH ₃ CN) ₄ PF ₆	THF	KO ^t Bu	(R)-Josiphos (5)	68	>98:2	48
9	Cu(CH ₃ CN) ₄ PF ₆	THF	KO ^t Bu	(R)-Fesulphos (6)	78	>98:2	68
10	Cu(CH ₃ CN) ₄ PF ₆	toluene	KO ^t Bu	(R)-Fesulphos (6)	78	>98:2	84
11 ^d	Cu(CH ₃ CN) ₄ PF ₆	toluene	KO ^t Bu	(R)-Fesulphos (6)	59	>98:2	90
12 ^e	Cu(CH ₃ CN) ₄ PF ₆	toluene	KO ^t Bu	(R)-Fesulphos (6)	93	>98:2	90
13 ^{d,e,f}	Cu(CH ₃ CN) ₄ PF ₆	toluene	KO ^t Bu	(R)-Fesulphos (6)	84	>98:2	90
14 ^{d,e,g}	Cu(CH ₃ CN) ₄ PF ₆	toluene	KO ^t Bu	(R)-Fesulphos (6)	66	>98:2	90

^aIsolated yield. ^bDetermined by ¹H NMR. ^cDetermined by HPLC. ^dReaction run at 0 °C. ^e2 equiv of **1a**. ^f5 mol % of catalyst. ^g3 mol % of catalyst.


56 demanding substrates could participate in this reaction.
57 Furthermore, the resulting cycloadducts could be interesting
58 scaffolds for further transformations.

59 We chose iminoester **1a** and 3-phenylcyclobutenone **2a** as
60 model substrates to optimize the reaction conditions. We began
61 studying the effect of the metal source and the base in the
62 presence of (±)-Binap as a ligand and THF as a solvent (see
63 **Table 1**, entries 1–6). The use of Et₃N in combination with
64 either silver or copper salts failed to promote the cycloaddition
65 (**Table 1**, entries 1 and 2). Satisfyingly, a stronger base such a
66 KO^tBu or KHMDS provided the expected cycloadduct with
67 moderate yield and almost complete endo selectivity (**Table 1**,
68 entries 3–6). The combination of Cu(CH₃CN)₄PF₆ and
69 KO^tBu afforded the best result (**Table 1**, entry 6).

70 Once we demonstrated the viability of the reaction, a survey
71 of chiral ligands were tested (**Table 1**, entries 7–14). A
72 promising 36% ee was obtained with (R)-binap (**Table 1**, entry
73 7). After further screening of ferrocenyl ligands, we found that a
74 Fesulphos ligand was the most efficient, furnishing the
75 azabicyclo **endo-3** in 78% yield and 68% ee (**Table 1**, entry
76 9). The enantioselectivity increased to 84% ee by performing
77 the reaction in toluene (**Table 1**, entry 10) and lowering the
78 temperature to 0 °C led to an additional improvement to 90%
79 ee, albeit with a lower yield (59% yield; see **Table 1**, entry 11).
80 Interestingly, an excellent yield was obtained using an excess of
81 the iminoester (2 equiv, 93%; see **Table 1**, entry 12). A similar
82 outcome was observed when the catalyst loading was reduced
83 to 5 mol % (**Table 1**, entry 13), but additional reduction to 3
84 mol % led to a significant decrease in the reactivity (66% yield;
85 see **Table 1**, entry 14).

86 The substrate scope with regard to the iminoester was next
87 evaluated (see **Scheme 2**). First, an array of iminoesters derived
88 from aromatic aldehydes was examined. The [3 + 2]
89 cycloaddition with either electron-donating or electron-with-
90 drawing substituents at the *para* position of the aromatic ring
91 afforded selectively the corresponding *endo*-azabicycles **3b–3d**
92 with good yields (73%–84%) and asymmetric inductions


Scheme 2. Scope with Regard to the Azomethine Ylide Precursor



ranging from 81% to 98% ee. Aromatic iminoesters with *meta* 93
or *ortho* substituents provided a similar result (cycloadducts 94
3e–3g), as well as the 1-naphthyl derivative (adduct **3h**).The 95
cycloaddition was equally effective with heteroaromatic- 96
substituted iminoesters such as furyl **1i** and thienyl **1j**. 97
Interestingly, the less-reactive cyclohexyl iminoester **1k** proved 98
also to be a suitable substrate, leading to the pyrrolidine *endo*- 99
3k with 64% yield and 72% ee. 100

101 The absolute and relative configuration of azabicyclo *endo*-3g
 102 was unambiguously established by X-ray diffraction (XRD) of
 103 its corresponding benzyl derivative.¹⁰ The observed enantioselectivity
 104 is in agreement with the model proposed to explain the
 105 origin of the high enantiocontrol attained by a Cu^I/(R)-
 106 Fesulphos complex in 1,3-dipolar cycloadditions.¹¹ Thus, the
 107 approach of the cyclobutenone would occur by the less-
 108 hindered face of the tetrahedral Fesulphos-iminoester copper
 109 complex, avoiding the steric interaction with the bulky ^tBu
 110 group (see Scheme 3).


Scheme 3. X-ray Structure of *endo*-3g^a and Proposed Stereochemical Model



^aHydrogen atoms have been removed for the sake of clarity.

111 The scope of the reaction regarding the substitution at the
 112 cyclobutenone partner is summarized in Scheme 4. Under the


Scheme 4. Scope with Regard to the Cyclobutenone



113 previously optimized reaction conditions, all the [3 + 2]
 114 cycloadditions occurred with practically complete diastereoselectivity
 115 and high enantioselectivity, regardless of the *para* or
 116 *ortho* position of the substituent at the aromatic ring of the 3-
 117 arylcyclobutenone (adducts 3l–3n). Outstandingly, the sterically
 118 very demanding 2,3-diphenyl cyclobutenone 2e also
 119 reacted satisfactorily, affording the adduct 3o, because of two
 120 adjacent all-carbon quaternary stereocenters, in 64% yield and
 121 84% ee.

122 In order to highlight the versatility of the bicyclic adducts to
 123 the enantioselective synthesis of fused pyrrolidine derivatives,
 124 some transformations were conducted (see Scheme 5).
 125 Treatment of *endo*-3a (90% ee) with benzyl chloroformate in
 126 the presence of K₂CO₃ afforded the corresponding enantio-
 127 enriched carbamate 7, which was readily transformed to the

Scheme 5. Synthetic Transformations of *endo*-3a



corresponding bicyclic lactone 8 (72% yield) by Baeyer–
 Villiger oxidation, using the standard conditions. A reduction of
 carbamate 7 with LiAlH₄ provided selectively the diol 9, while
 carbonyl reduction with NaBH₄, followed by treatment with a
 cationic gold complex, led to the tricyclic transesterification
 product 11. Products 8–11 were isolated as single diastere-
 omers with similar enantiopurity (90% ee)

In conclusion, a practical asymmetric [3 + 2] cycloaddition of
 azomethine ylides and cyclobutenones has been developed. In
 the presence of Cu^I/(R)-Fesulphos as a catalyst system, this
 reaction delivered valuable 3-azabicyclo[3.2.0]-heptanes with
 very high diastereoselectivity and excellent enantioselectivity.
 The synthetic potential of the cycloaddition was highlighted by
 the preparation of a variety of fused pyrrolidine derivatives.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the
 ACS Publications website at DOI: 10.1021/acs.orglett.8b00936.

Experimental procedures, ¹H and ¹³C NMR spectra for
 all new compounds, copies of HPLC chromatograms
 used to determine the enantiomeric purity (PDF)

Accession Codes

CCDC 1828413 contains the supplementary crystallographic
 data for this paper. These data can be obtained free of charge
 via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge
 Crystallographic Data Centre, 12 Union Road, Cambridge CB2
 1EZ, U.K.; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: javier.adrio@uam.es (J. Adrio).

*E-mail: juancarlos.carretero@uam.es (J. C. Carretero).

ORCID

Javier Adrio: 0000-0001-6238-6533

163 Author Contributions

164 §The manuscript was written through contributions of all
165 authors. All authors have given approval to the final version of
166 the manuscript. These authors contributed equally.

167 Notes

168 The authors declare no competing financial interest.

169 ■ ACKNOWLEDGMENTS

170 Financial support of this work by the Ministerio de Economía,
171 Industria y Competitividad and Fondo Europeo de Desarrollo
172 Regional (Project Nos. CTQ2012-35790 MINECO and
173 CTQ2015-66954-P MINECO/FEDER, UE) is gratefully
174 acknowledged. A.P. thanks the MICINN for a predoctoral
175 fellowship. J.C. thanks the MECED for a FPU predoctoral
176 fellowship. We thank the Takasago Company (Dr. Taichiro
177 Touge) for the generous loans of Segphos chiral ligands.

178 ■ REFERENCES

179 (1) (a) Kuhnert, M.; Blum, A.; Steuber, H.; Diederich, W. E. *J. Med.*
180 *Chem.* **2015**, *58*, 4845. (b) Taylor, R. D.; MacCoss, M.; Lawson, A. D.
181 *G. J. Med. Chem.* **2014**, *57*, 5845. (c) Roughley, S. D.; Jordan, A. M. *J.*
182 *Med. Chem.* **2011**, *54*, 3451. (d) Michael, J. P. *Nat. Prod. Rep.* **2008**, *25*,
183 139. (e) Daly, J. W.; Spande, T. F.; Garraffo, H. M. *J. Nat. Prod.* **2005**,
184 *68*, 1556. (f) Pyne, S. G.; Davis, A. S.; Gates, N. J.; Hartley, J. P.;
185 Lindsay, K. B.; Machan, T.; Tang, M. *Synlett* **2004**, *2004*, 2670.
186 (g) Cheng, Y.; Huang, Z.-T.; Wang, M.-X. *Curr. Org. Chem.* **2004**, *8*,
187 325.
188 (2) (a) Denisenko, A. V.; Druzhenko, T.; Skalenko, Y.; Samoilenko,
189 M.; Grygorenko, O. O.; Zozulya, S.; Mykhailiuk, P. K. *J. Org. Chem.*
190 **2017**, *82*, 9627. (b) Tari, L. W.; Li, X.; Trzoss, M.; Bensen, D. C.;
191 Chen, Z.; Lam, T.; Zhang, J.; Lee, S. J.; Hough, G.; Phillipson, D.;
192 Akers-Rodríguez, S.; Cunningham, M. L.; Kwan, B. P.; Nelson, K. J.;
193 Castellano, A.; Locke, J. B.; Brown-Driver, V.; Murphy, T. M.; Ong, V.
194 S.; Pillar, C. M.; Shinabarger, D. L.; Nix, J.; Lightstone, F. C.; Wong, S.
195 E.; Nguyen, T. B.; Shaw, K. J.; Finn, J. *PLoS One* **2013**, *8*, e84409.
196 (c) McKenzie, T. C.; Epstein, J. W.; Fanshawe, W. J.; Dixon, J. S.;
197 Osterberg, A. C.; Wennogle, L. P.; Regan, B. A.; Abel, M. S.;
198 Meyerson, L. R. *J. Med. Chem.* **1984**, *27*, 628.
199 (3) For the synthesis of racemic 3-azabicyclo[3.2.0]heptanes, see:
200 (a) Petz, S.; Wanner, K. T. *Eur. J. Org. Chem.* **2013**, *2013*, 4017.
201 (b) Kriis, K.; Ausmees, K.; Pehk, T.; Lopp, M.; Kanger, T. *Org. Lett.*
202 **2010**, *12*, 2230. For a kinetic enzymatic resolution of a racemate, see:
203 (c) Reinart-Okugbeni, R.; Ausmees, K.; Kriis, K.; Werner, F.; Rincken,
204 A.; Kanger, T. *Eur. J. Med. Chem.* **2012**, *55*, 255.
205 (4) For recent reviews, see: (a) Adrio, J.; Carretero, J. C. *Chem.*
206 *Commun.* **2014**, *50*, 12434. (b) Hashimoto, T.; Maruoka, K. *Chem. Rev.*
207 **2015**, *115*, 5366. (c) Bdiri, B.; Zhao, B.-J.; Zhou, Z.-M. *Tetrahedron:*
208 *Asymmetry* **2017**, *28*, 876. (d) Döndas, H. A.; de Gracia Retamosa, M.;
209 Sansano, J. M. *Synthesis* **2017**, *49*, 2819. (e) Nájera, C.; Sansano, J. M.
210 *J. Organomet. Chem.* **2014**, *771*, 78. (f) Xing, Y.; Wang, N.-X. *Coord.*
211 *Chem. Rev.* **2012**, *256*, 938. (g) Adrio, J.; Carretero, J. C. *Chem.*
212 *Commun.* **2011**, *47*, 6784.
213 (5) For selected recent references, see: (a) Esteban, F.; Ciéslik, W.;
214 Arpa, E. M.; Guerrero-Corella, A.; Díaz-Tendero, S.; Perles, J.;
215 Fernández-Salas, J. A.; Fraile, A.; Alemán, J. *ACS Catal.* **2018**, *8*, 1884.
216 (b) Harada, M.; Kato, S.; Haraguchi, R.; Fukuzawa, S.-i. *Chem.—Eur. J.*
217 **2018**, *24*, 2580. (c) Feng, B.; Chen, J.-R.; Yang, Y.-F.; Lu, B.; Xiao, W.-
218 *J. Chem.—Eur. J.* **2018**, *24*, 1714. (d) Xu, S.; Zhang, Z.-M.; Xu, B.; Liu,
219 B.; Liu, Y. Y.; Zhang, J. *J. Am. Chem. Soc.* **2018**, *140*, 2272. (e) Molina,
220 A.; Pascual-Escudero, A.; Adrio, J.; Carretero, J. C. *J. Org. Chem.* **2017**,
221 *82*, 11238. (f) Deng, H.; He, F.-S.; Li, C.-S.; Yang, W.-L.; Deng, W.-P.
222 *Org. Chem. Front.* **2017**, *4*, 2343. (g) Liu, Y.-Z.; Shang, S.-J.; Yang, W.-
223 L.; Luo, X.; Deng, W.-P. *J. Org. Chem.* **2017**, *82*, 11141. (h) Hou, Y.;
224 Zhou, Z.; Liu, P.; Wang, J. K.; Hou, Q.; Wen, P.; Wang, H.
225 *Tetrahedron: Asymmetry* **2017**, *28*, 930. (i) Zhou, Z.; Zheng, X.; Liu, J.;
226 Li, J.; Wen, P.; Wang, H. *Synlett* **2017**, *28*, 999. (j) Bdiri, B.; Dai, L.;

Zhou, Z.-M. *Tetrahedron Lett.* **2017**, *58*, 2475. (k) Xu, B.; Zhang, Z.-
227 M.; Xu, S.; Liu, B.; Xiao, Y.; Zhang, J. *ACS Catal.* **2017**, *7*, 210. 228
(6) Hernandez-Toribio, J.; Gómez Arrayás, R.; Martín-Matute, B.;
229 Carretero, J. C. *Org. Lett.* **2009**, *11*, 393. 230
(7) (a) Oura, I.; Shimizu, K.; Ogata, K.; Fukuzawa, S.-i. *Org. Lett.* 231
2010, *12*, 1752. (b) Nájera, C.; de Gracia Retamosa, M.; Martín- 232
Rodríguez, M.; Sansano, J. M.; de Cózar, A.; Cossío, F. P. *Eur. J. Org.* 233
Chem. **2009**, *2009*, S622. (c) Zhang, C.; Yu, S.-B.; Hu, X.-P.; Wang, D.- 234
Y.; Zheng, Z. *Org. Lett.* **2010**, *12*, 5542. 235
(8) (a) Zhang, Z. M.; Xu, B.; Xu, S.; Wu, H. H.; Zhang, J. *Angew.* 236
Chem., Int. Ed. **2016**, *55*, 6324. (b) Xu, B.; Zhang, Z. M.; Liu, B.; Xu, 237
S.; Zhou, L.-J.; Zhang, J. *Chem. Commun.* **2017**, *53*, 8152. 238
(9) (a) Li, X.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2010**, *132*, 11004. 239
(b) Ross, A. G.; Townsend, S. D.; Danishefsky, S. J. *J. Org. Chem.* 240
2013, *78*, 204. (c) Ross, A. G.; Li, X.; Danishefsky, S. J. *J. Am. Chem.* 241
Soc. **2012**, *134*, 16080. 242
(10) See the [Supporting Information](#). 243
(11) Cabrera, S.; Gómez Arrayás, R.; Martín-Matute, B.; Cossío, F. 244
P.; Carretero, J. C. *Tetrahedron* **2007**, *63*, 6587. 245